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OBJECTIVE—An emerging model of metabolic syndrome and
type 2 diabetes is of adipose dysfunction with leukocyte recruit-
ment into adipose leading to chronic inﬂammation and insulin
resistance (IR). This study sought to explore potential mecha-
nisms of inﬂammatory-induced IR in humans with a focus on
adipose tissue.
RESEARCH DESIGN AND METHODS—We performed a 60-h
endotoxemia protocol (3 ng/kg intravenous bolus) in healthy
adults (n  20, 50% male, 80% Caucasian, aged 27.3  4.8 years).
Before and after endotoxin, whole-blood sampling, subcutaneous
adipose biopsies, and frequently sampled intravenous glucose
tolerance (FSIGT) testing were performed. The primary outcome
was the FSIGT insulin sensitivity index (Si). Secondary measures
included inﬂammatory and metabolic markers and whole-blood
and adipose mRNA and protein expression.
RESULTS—Endotoxemia induced systemic IR as demonstrated
by a 35% decrease in Si (3.17  1.66 to 2.06  0.73  10
4 [U 
ml
1  min
1], P  0.005), while there was no effect on pancreatic
-cell function. In adipose, endotoxemia suppressed insulin
receptor substrate-1 and markedly induced suppressor of cyto-
kine signaling proteins (1 and 3) coincident with local activation
of innate (interleukin-6, tumor necrosis factor) and adaptive
(monocyte chemoattractant protein-1 and CXCL10 chemokines)
inﬂammation. These changes are known to attenuate insulin
receptor signaling in model systems.
CONCLUSIONS—We demonstrate, for the ﬁrst time in humans,
that acute inﬂammation induces systemic IR following modula-
tion of speciﬁc adipose inﬂammatory and insulin signaling path-
ways. It also provides a rationale for focused mechanistic studies
and a model for human proof-of-concept trials of novel therapeu-
tics targeting adipose inﬂammation in IR and related conse-
quences in humans. Diabetes 59:172–181, 2010
A
dipose dysfunction, insulin resistance (IR), and
type 2 diabetes are proinﬂammatory states.
Indeed, gene manipulation of Toll-like recep-
tors (1,2), chemokines (3,4), and cytokines in
experimental models has deﬁned a role of innate and
adaptive immunity in diet-induced adipose dysfunction
and IR. An emerging model is one of early adipose
recruitment of T-cells and macrophages with adipocyte
inﬂammation and resistance to insulin-promoting meta-
bolic syndrome, type 2 diabetes, and atherosclerosis.
Experimental data suggest that inﬂammation may attenu-
ate adipocyte insulin signaling. Dietary and inﬂammatory
activation of the inhibitor of nuclear factor B kinase -sub-
unit (IKK), c-Jun NH2-terminal kinase (JNK) (5), protein
kinase C (PKC) (6), and janus tyrosine kinases (JAK)/signal
transducers and activators of transcription (STAT) (7) have
been implicated in IR in adipocytes and rodent experimental
models (7). These inﬂammatory kinases may promote IR by
downregulating components of the insulin signaling cascade,
including the insulin receptor and insulin receptor substrates
(IRSs), and by inducing suppressors of cytokine signaling
(SOCS), inhibitors of insulin receptor signaling. Despite
substantial data in animal models, however, little is known of
the speciﬁc role and mechanisms of inﬂammatory IR in
humans. Deﬁning whether adipose inﬂammation occurs in
human IR and which speciﬁc pathways are involved will
provide greater insight into human pathophysiology and
inform preventive and therapeutic strategies for type 2 dia-
betes and its complications.
We and others utilize low-dose experimental endotox-
emia to activate Toll-like receptor (TLR)-4 signaling in vivo
as a model of inﬂammation-induced metabolic distur-
bances in humans (8–10). Here, we deﬁne the effects of
endotoxemia on insulin sensitivity and focus on adipose
inﬂammation because of its emerging relevance in di-
etary excess and adipose dysfunction in human IR. We
demonstrate, for the ﬁrst time in humans, that activation
of innate immunity in vivo induces IR following modu-
lation of speciﬁc adipose inﬂammatory and insulin
signaling pathways.
RESEARCH DESIGN AND METHODS
Healthy volunteers were recruited from the general population of the Dela-
ware Valley (10). The protocol was approved by the institutional review board
of the University of Pennsylvania, and subjects gave written informed consent.
Full details are described in the online appendix (available at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-0367/DC1). Brieﬂy, criteria included
healthy men or nonpregnant/lactating women, aged 18–40 years, with BMI of
18–30 kg/m
2. Twenty subjects were recruited, equally divided by sex, to the
University of Pennsylvania’s Clinical Translational Research Center for three
visits: visit 1 for screening; visit 2, 2 weeks later, for frequently sampled
intravenous glucose tolerance (FSIGT) testing and dietary counseling; and
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phase, and a 24-h post-lipopolysaccharide (LPS) study phase (60-h total). LPS
(U.S. standard reference endotoxin, lot no. CC-RE-LOT-1 	 2; Clinical Center,
Pharmacy Department, National Institutes of Health) was given intravenously
as a 3 ng/kg bolus at 0600 h on day 2. Blood samples (nine before and nine
after LPS) and subcutaneous gluteal adipose aspiration-biopsy samples (be-
fore and 4, 12, and 24 h after LPS) were collected (in n  17 participants;
621.4  253.1 mg average weight per sample).
Laboratory measures. Two weeks prior to LPS and 24 h following LPS, the
insulin sensitivity index (Si) was derived from an FSIGT test. We chose the 24-h
post-LPS because we expected IR to be established by this time point based on
human and animal experimental and observational data (8,10–12) and because of
practical considerations given the experimental design. We chose FSIGT as the
method for determining insulin sensitivity because the test also provides a
measure of pancreatic -cell function, the acute insulin response to glucose
(AIRg), and so allows assessment of endotoxemia effects on the -cell. The FSIGT
test was conducted using the insulin-modiﬁed approach as previously described
(13). Si was derived from Bergman’s minimal model (14) using MINMOD
Millennium software (15). AIRg was calculated as the incremental area under the
curve for insulin from t  0 to 10 min (12). Complementary estimates of IR and
-cell function, the homeostasis model assessment for IR (HOMA-IR) index
[glucose (mmol/l)  insulin (U/ml)/22.5], and the HOMA for -cell function
(HOMA-B) index [insulin (U/ml)  20/glucose (mmol/l)  3.5] were calculated
using fasting glucose and insulin values at 24 h and 5 min before and 24 h after
LPS. Plasma biomarkers and lipoprotein measurement was described previously
(10) and is outlined in the online appendix.
RNA isolation, real-time PCR quantiﬁcation of mRNAs, and adipose protein
isolation for Western blotting are described in detail in the online appendix.
RNA extraction was performed for measurement of mRNA levels of interleu-
kin (IL)-6, tumor necrosis factor (TNF)-
, TNF-induced protein 3 (A20),
resistin, SOCS-1, SOCS-2, SOCS-3, SOCS-6, insulin receptor, IRS-1, IRS-2,
IRS-3, IRS-4, GLUT4, and chemokines monocyte chemoattractant protein-1
(MCP-1) and C-X-C motif ligand 10 (CXCL10) (online appendix Table 1).
Macrophage marker human epidermal growth factor module–containing
mucin-like receptor 1 (EMR1-F4/80) mRNA also was assayed in adipose.
Statistical analysis. Data are reported as means  SE for continuous
variables and as proportions for categorical variables. In general, the effect of
endotoxemia on plasma biomarkers, metabolic measures, blood and adipose
mRNAs, and adipose protein levels were tested by mixed-effects modeling or
repeated-measures ANOVA. For plasma data, we considered the time-matched
difference (after minus before for matched time points prior to and following
LPS) in biomarker responses and used a mixed-effects model to consider the
effect due to LPS. A variety of models including linear, quadratic, and cubic
polynomial were ﬁt, and the best ﬁt for each variable was used for ﬁnal
analyses (e.g., quadratic models for TNF, IL-6, and resistin). A similar
time-matched mixed-effect modeling approach was applied to whole-blood
mRNA data. Repeated-measures ANOVA was applied to FSIGT data (Si and
AIRg), HOMA data (HOMA-IR and HOMA-B), and adipose mRNA data. When
signiﬁcant global differences were found in ANOVA, post hoc paired t tests
were used to compare time points. Analyses were performed using the
freeware statistical package R (version 2.4.1; The R Foundation for Statistical
Computing). Statistical signiﬁcance was deﬁned as a P value 0.05.
RESULTS
Baseline characteristics of participants and clinical
responses to endotoxemia. Participants were healthy
adults volunteers (n  20, 50% male, 80% Caucasian, aged
25.7  3.9 years). They had normal blood pressure, plasma
lipoproteins, BMI, and body fat distribution (Table 1), and
baseline Si and HOMA-IR were consistent with data from
healthy subjects published by our group (13). Endotoxemia
produced a transient febrile illness in all subjects with
increases in temperature, heart rate, and white blood cell
count largely resolving by 8–12 h following LPS (Table 2).
Systemic inﬂammatory and metabolic responses. We
have previously described plasma adipokine responses in
this study sample (10). Brieﬂy, endotoxemia induced a
marked, rapid, and transient induction of plasma TNF and
IL-6 (Table 2), followed by a robust increase in circulating
resistin and a delayed but signiﬁcant increase in leptin and
leptin-soluble leptin ratio in plasma. We now report signif-
icant increases in additional circulating inﬂammatory
markers including MCP-1 and high-sensitivity C-reactive
protein (hsCRP) (Fig. 1A) as well as plasma cortisol and
free fatty acids, with a trend toward increased growth
hormone (GH) (P  0.08) levels (Fig. 1B). Overall, these
ﬁndings conﬁrm a transient inﬂammatory response during
human endotoxemia with modulation of several inﬂamma-
tory, adipokine, and hormonal cascades that are known to
impact insulin sensitivity.
Experimental endotoxemia induces IR in humans. We
hypothesized that these inﬂammatory and metabolic per-
turbations would induce IR without altering pancreatic
-cell function. Insulin sensitivity, measured as Si,d e -
clined by over 30% from 2 weeks prior to 24 h after LPS
(3.17  1.66 to 2.06  10
4 [U  ml
1  min
1], P  0.005)
(Fig. 2A). In contrast, AIRg, a measure of pancreatic -cell
function, showed no change following LPS (711  418 to
744  488 U  ml
1  min
1, P  0.7) (Fig. 2B). Consistent
with the FSIGT data, HOMA-IR was 39 and 46% higher at 24 h
after LPS (2.17  0.83) than 24 h (1.56  0.62; P  0.001) and
5 min (1.49  0.63; P  0.001) prior to LPS (Fig. 2C), while
HOMA-B, an estimate of pancreatic -cell function, was not
TABLE 1
Baseline characteristics of study participants
Age (years) 25.7  3.90
Blood pressure
Systolic 116  15
Diastolic 67  8
Total cholesterol (mmol/l) 4.53  0.52
HDL cholesterol (mmol/l)
Male 1.33  0.26
Female 1.69  0.34
Triglycerides (mmol/l) 0.86  0.39
Fasting glucose (mmol/l) 4.68  0.28
BMI (kg/m
2)
Male 24.27  1.62
Female 23.37  0.78
Waist circumference (cm)
Male 83.9  5.81
Female 82.8  5.1
Total body fat dual-energy X-ray
absorptiometry (%)
Male 15.3  3.4
Female 29.7  3.3
FSIGT-Si (10
4 U  ml
1  min
1) 3.17  1.66
HOMA-IR insulin resistance index 1.56  0.63
FSIGT-AIRg (U  ml
1  min
1) 701  120
HOMA-B -cell function index 104  36
Data are means  SD.
TABLE 2
Peak clinical and systemic inﬂammatory responses during
endotoxemia
Pre-LPS Post-LPS
Time of
peak (h)
Plasma IL-6
(ng/ml) 3.2  17.1 1,607  650* 2
Plasma TNF
(ng/ml) 3.0  1.1 507  251* 2
Heart rate (bpm) 83  11 103  14 4
Temperature (°C) 36.5  0.5 37.7  1.0† 4
White blood cell
count (mg/l) 6.5  0.9 12.9  4.1† 12
Plasma hsCRP 0.49  0.21 42.4  8.4† 24
Clinical parameters and plasma levels of cytokines are presented as
means  SD. *P  0.0001; †P  0.005.
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observed a modest negative correlation (Spearman R 
0.51) between HOMA-IR and Si consistent with prior work
highlighting the differences in fasting versus evoked physiol-
ogy captured by these indexes (16).
We explored whether peak levels of inﬂammatory and
metabolic biomarkers (TNF, IL-6, MCP-1, hsCRP, resistin,
cortisol, GH, or free fatty acids) correlated with the degree
of induced IR. We found that peak hsCRP (Spearman R 
0.57, P  0.03) and resistin (r  0.47, P  0.08) tended to
correlate with change in HOMA-IR, a measure of hepatic
IR, while the peak FFA levels were inversely correlated
(r  0.81, P  0.004) with Si, a measure of peripheral
insulin sensitivity.
Endotoxemia induces adipose inﬂammation in humans.
Endotoxemia induced a robust innate inﬂammatory re-
sponse in adipose with increases in mRNA levels of IL-6
(peak 110-fold, ANOVA F  64.5, P  0.001), TNF (peak
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FIG. 1. Plasma levels of inﬂammatory and hormonal markers. A: Endotoxemia increased plasma TNF-, MCP-1, and hsCRP. B: Plasma cortisol and
free fatty acids increased signiﬁcantly with a trend for increase in GH (P  0.08). Inset graphs show the difference for 24 h after versus 24 h
before LPS. *P < 0.0001 and †P < 0.005 in mixed-effects model.
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P  0.001) (Fig. 3A). In parallel, adipose mRNA levels of
MCP-1 (peak 30-fold, F  3.49, P  0.03), a chemokine
implicated in adipose macrophage recruitment (3,4), and
CXCL10 (peak 15-fold, F  8.5, P  0.005), a T-cell
chemokine, were markedly induced during endotoxemia
(Fig. 3B). Supporting these mRNA changes, protein levels
of both A20 and MCP-1 were signiﬁcantly increased in
adipose at Western blotting (Fig. 3C). Remarkably, adi-
pose mRNA levels of resistin (fourfold, F  6.9, P  0.001),
a leukocyte-derived cytokine in humans, and EMR1-F4/80
(peak 13-fold, F  13.8, P  0.001), a macrophage marker,
were increased, suggesting recruitment of leukocytes to
adipose during endotoxemia.
Endotoxemia modulates the insulin signaling path-
way in adipose and blood. We sought evidence that
adipose inﬂammation modulated insulin signaling pathways
in adipose. SOCS family proteins inhibit tyrosine kinase
receptor signaling including the insulin receptor. At baseline
prior to LPS, SOCS-3, SOCS-6, and SOCS-2 mRNAs were the
most abundant in human adipose with evidence of differen-
tial expression compared with whole blood (supplementary
Table 2). Following endotoxin, adipose SOCS-1 (10-fold) and
SOCS-3 (20-fold), but not SOCS-2 or SOCS-6, mRNAs in-
creased markedly (Fig. 4A). There were similar striking
changes in whole-blood SOCS-1 and SOCS-3 (3-fold and
30-fold, respectively), but endotoxin actually reduced
SOCS-2 and SOCS-6 mRNA in blood (Fig. 4B).
IRS family members are key mediators of cellular insu-
lin signaling. Prior to LPS, we detected mRNA for IRS-1
and IRS-2 but not IRS-3 or IRS-4 in adipose with differen-
tial expression compared with whole blood (supplemen-
tary Table 2). Endotoxin reduced IRS-1 (by 47%) mRNA in
adipose. In whole blood, IRS-1 mRNA levels also fell (by
53%), but IRS-2 mRNA increased (2.3-fold increase) (Table
3). In parallel, insulin receptor mRNA levels decreased
signiﬁcantly in blood but not in adipose, and there was no
signiﬁcant change in GLUT4 mRNA in adipose or whole
blood (Table 3). Western blotting of adipose proteins
generally supported mRNA data with reduction in IRS-1
but no change in insulin receptor; however, GLUT4 protein
levels tended to fall (Fig. 5). Furthermore, enhanced serine
phosphoryation of AKT, with no change in total AKT (Fig.
5), was observed consistent with previous ﬁndings of
TNF-induced serine phosphorylation of AKT in adipocytes
(17). Overall, endotoxemia induced speciﬁc SOCS proteins
and modulated several components of the insulin signaling
pathway in adipose.
DISCUSSION
Inﬂammation, particularly in adipose tissue, has been
implicated in diet- and obesity-related IR in experimental
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states of infection and sepsis. However, the speciﬁc mech-
anisms and the potential for therapeutic targeting in
humans are poorly understood. In this work, we found that
endotoxemia induced systemic IR but not pancreatic
-cell dysfunction in humans. Further, IR measured at 24 h
post-LPS was preceded by speciﬁc modulation of adipose
inﬂammatory and insulin signaling pathways. This work
deﬁnes speciﬁc targets for inﬂammatory modulation of
insulin signaling in humans and also provides a human
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in IR and its complications.
Epidemiological studies (18,19) suggest causal links
between chronic inﬂammation, IR, and incident type 2
diabetes, while observational data demonstrate that IR
and overt type 2 diabetes may emerge during human
infections and sepsis (11). Agwunobi et al. (8) were the
ﬁrst to show impaired insulin sensitivity 6–7 h following
LPS administration utilizing euglycemic clamp studies.
Our study goes beyond the ﬁndings of Agwunobi et al. by
demonstrating persistence of IR at 24 h after endotoxin in
the absence of any effect on pancreatic -cell function
while also identifying adipose tissue inﬂammatory re-
sponses and modulation of speciﬁc adipose insulin signal-
ing proteins that precede systemic IR. Interestingly,
Agwunobi et al. also noted enhanced insulin sensitivity 2 h
after LPS as determined by a signiﬁcant increase in the
glucose infusion rate required during the clamp. A recent
elegant study (20) using isotope tracers with a euglycemic
clamp showed that this acute and transient increase in
insulin sensitivity at 1–2 h after LPS was due to increases
in both hepatic and peripheral insulin sensitivity.
Experimental models support an important role for
innate and adaptive immunity in diet- and obesity-induced
IR (1,3–5,21). Deﬁciency of TLR-4, the innate antigen/LPS
receptor, protects against diet-induced obesity and IR in
TABLE 3
Insulin signaling proteins are modulated in adipose and whole blood during endotoxemia
Gene
Adipose mRNA expression Blood mRNA expression
Maximal
percent change Time (h)
ANOVA
P value
Maximal
percent change Time (h)
Mixed-effects
model P value
Insulin receptor 25 12 0.26 20 2 0.001
IRS-1 47 4 0.03 53 4 0.03
IRS-2 25 4 0.36 	230 12 0.001
IRS-3 ND — — 50 4 0.001
GLUT4 24 12 0.33 25 12 0.02
ND, not detected.
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FIG. 5. Western blot of insulin signaling proteins in adipose tissue. Relative to -actin, endotoxin reduced protein levels of IRS-1 and GLUT4,
increased phosphorylated-AKT (p-AKT), and had no effect on insulin receptor expression (representative blot shown; densitometry for IRS-1 and
p-AKT n  3; *ANOVA P < 0.01).
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posal, and functional TNF deﬁciency in mice protects from
obesity-induced IR (21). However, the relevance to human
pathophysiology of individual signaling pathways impli-
cated in rodent models remains unknown. In fact, species
heterogeneity in inﬂammatory modulation (22) and of
insulin signaling has been documented (9,23). Thus, use of
human models of inﬂammation can provide unique insight
into clinically relevant mechanisms and therapeutic tar-
gets for IR and type 2 diabetes.
Our study is the ﬁrst to demonstrate loss of insulin
sensitivity without any apparent effect on pancreatic -cell
function during acute human inﬂammation. Because fast-
ing-based HOMA-IR estimates have been shown to corre-
late best with measures of hepatic insulin sensitivity and
FSIGT Si with measures of peripheral insulin sensitivity
(24), endotoxemia appears to trigger both hepatic and
peripheral IR. Indeed, we note that Agwunobi et al. (8)
published data with euglycemic clamps that demonstrate
hepatic IR following LPS. Further, we describe several
inﬂammatory perturbations that may impact tissue and
systemic insulin sensitivity, induction of inﬂammatory
cytokines and chemokines, modulation of adipokine sig-
naling (10), activation of the hypothalamic-pituitary-adre-
nal axis (25), and altered ﬂux of plasma free fatty acids
(26). Indeed, the degree of evoked change in several
inﬂammatory and metabolic markers, including free fatty
acids, hsCRP, resistin, and GH tended to precede and
correlate with the degree of IR. Taken together, therefore,
these data support a model of both hepatic and peripheral
IR during endotoxemia, with peripheral IR likely to be
occurring at the level of skeletal muscle as well as adipose
tissue.
Recent experimental studies in rodents demonstrated
that adipose recruitment of T-cell and macrophages in
obesity promotes adipocyte inﬂammation leading to local
and systemic IR (27). We hypothesized that adipose in-
ﬂammation would be a consequence of human endotox-
emia that might contribute to local and systemic IR.
Endotoxemia induced a rapid and transient increase in
adipose TNF and IL-6. There was also a marked induction
of adipose MCP-1, which is known to recruit chemokine
CC motif receptor (CCR)-2–expressing monocytes, in-
crease inﬂammatory-M1 adipose tissue macrophage
(ATM), and promote IR (27). Recent studies of diet-
induced obesity suggest that upregulation of T-cell chemo-
kines in adipose and recruitment of inﬂammatory TH1
cells precedes recruitment of monocytes and the develop-
ment of systemic IR. Remarkably, we found that endotox-
emia induced CXCL10, a potent T-cell chemokine. The
emergence of resistin mRNA in adipose suggests leuko-
cyte recruitment because expression of this adipokine is
restricted to myeloid lineage in humans (23). In addition,
we found increased mRNA levels of the macrophage
marker EMR1-F4/80 (28) in adipose, further supporting
that endotoxemia may promote adipose recruitment of
macrophages. Overall, these data suggest that endotox-
emia induces human adipose inﬂammatory responses sim-
ilar to those observed in models of diet- and obesity-
related IR (1–4,21,27).
Whether inﬂammation attenuates adipose insulin signal-
ing in humans and which signaling pathways are involved
has not been deﬁned. Several inﬂammatory adipokines
such as TNF, IL-6, and resistin, as well as endotoxin itself,
induce SOCS proteins that inhibit insulin receptor signal-
ing and target IRS proteins for ubiquitination and proteo-
somal degradation (29,30). The SOCS family, consisting of
eight members, is recognized as a general negative feed-
back mechanism for receptor tyrosine kinase signaling
including the insulin receptor. Using the yeast two-hybrid
system, SOCS-1, SOCS-3, and SOCS-6 have been shown to
bind to the insulin receptor (31), and cells from SOCS-1–
deﬁcient mice exhibit enhanced insulin sensitivity (30).
Conversely, in obesity, SOCS-1 and SOCS-3 are increased
in liver, muscle, and fat coincident with reduced tyrosine
phosphorylation of IRS proteins. We report for the ﬁrst
time the pattern of SOCS family mRNA expression in
human adipose and a marked and selective induction of
adipose SOCS proteins during endotoxemia; SOCS-1 and
SOCS-3 were increased with no effect of SOCS-2 and
SOCS-6. Our ﬁndings suggest that induction of SOCS-3 in
adipose may be an important molecular mechanism of IR
in human inﬂammatory states (31).
The in vivo effect of inﬂammation on insulin receptor
signaling in human adipose is unknown. The insulin recep-
tor, a transmembrane dimeric protein with intrinsic kinase
activity, recruits IRS proteins upon insulin binding. Ty-
rosine phosphorylation of IRS proteins activates phospha-
tidylinositol-3-kinase, leading to AKT phosphorylation and
GLUT4 mobilization (32). Inﬂammatory kinases including
IKK (5,33), JNK (5), PKCs (6), and JAK-STATs attenuate
insulin signaling in adipocytes and in rodent models.
These kinases induce serine phosphorylation of IRS-1,
which inhibits IRS-1 tyrosine phosphorylation during insu-
lin signaling (32). We found tissue-speciﬁc IRS expression
and downregulation of adipose IRS-1 protein coincident
with reduced IRS-1 mRNA. Our data also suggest species
heterogeneity in the pattern of adipose IRS expression
with more abundant IRS-2 in human adipose compared
with that reported in rodents (32). The effect of endotox-
emia on IRS-1 protein levels is one of several mechanisms
by which endotoxemia may impair insulin signaling in
human adipose. Remarkably, changes in several mRNAs in
whole blood paralleled that in adipose (e.g., IL-6, MCP1,
SOCS-1, and SOCS-3). However, inﬂammation appears to
modulate speciﬁc insulin signaling–related proteins (in-
sulin receptor, SOCS-2 and SOCS-6, and IRS-2) in a
tissue-speciﬁc manner. This should prompt caution in
extrapolating tissue-speciﬁc effects from global charac-
terization of whole-blood mRNAs.
Overall, endotoxemia induces IR in humans following
modulation of adipose tissue inﬂammatory and insulin
signal pathways in vivo. While adipose dysfunction in
genetically and environmentally susceptible patients may
increase inﬂammation, experimental endotoxemia may
also induce adipose inﬂammation and subsequent adipo-
cyte dysfunction, which then leads to IR. However, our
study has several limitations. While we have not deﬁni-
tively proven that adipose inﬂammation is causal in sys-
temic IR during endotoxemia, our work provides proof of
principle that inﬂammation-induced systemic IR emerges
after inﬂammatory modulation of adipose insulin signaling
in humans. We emphasize the need for speciﬁc study of the
chronic low-grade human inﬂammation observed in obe-
sity, metabolic syndrome, and type 2 diabetes. Our ap-
proach to study insulin sensitivity using the FSIGT-derived
Si at 24 h post-LPS is limited in that we cannot differentiate
various contributions of changes in hepatic and peripheral
insulin sensitivity versus the total body change and cannot
deﬁne the kinetics of the development and resolution of
IR. However, we utilized the FSIGT Si as a sensitive
measure of peripheral IR and combined this with the
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insulin sensitivity (24). Furthermore, FSIGT enabled ex-
amination of whether pancreatic -cell function changes
during inﬂammation-induced IR, while the hyperinsuline-
mic-eugylemic clamp does not. We acknowledge that
inﬂammatory effects are likely to occur in liver and in
skeletal muscle during endotoxemia and that these could
impact systemic IR. Indeed, our HOMA-IR data and our
FSIGT data support both hepatic and peripheral IR con-
sistent with published euglycemic clamp studies. Detailed
examination of changes in skeletal muscle and greater
study of adipose tissue inﬂammation and function in
relationship to the kinetics of IR is warranted in future
studies. Despite these limitations, our study provides the
ﬁrst tissue level data on evoked inﬂammatory pathways in
human IR.
Finally, endotoxemia may not represent accurately the
pathophysiology of chronic inﬂammatory, insulin-resistant
disease states. Several lines of evidence, however, support
its relevance to the pathophysiology of IR in humans. First,
an inﬂammatory IR and metabolic dyslipidemia emerges
clinically during acute sepsis (11) and chronic infections
(34). Second, we and others have shown that cytokine/
adipokine (10,23,35), acute-phase reactant responses, and
lipoprotein changes (36,37) observed acutely during
experimental endotoxemia resemble those chronically ob-
served in the metabolic syndrome. Third, gene manipula-
tion and drug targeting of the TLR-4 (2,38) and nuclear
factor B (5,39) have provided proof of concept that
modulation of innate immune signaling attenuates IR and
type 2 diabetes in dietary and obesity models. Last, and
directly relevant to the effect on adipose, we recently
demonstrated that endotoxemia induces gene expression
responses in subcutaneous adipose (40) that are remark-
ably similar to the changes observed in visceral adipose in
insulin-resistant states (41–43).
Conclusion. Human endotoxemia induces systemic IR
but not pancreatic -cell dysfunction. Remarkably, evoked
adipose inﬂammation and modulation of adipose insulin
signal pathways, similar to some of those described in
rodent models of diet-induced obesity and IR, precede the
emergence of systemic IR in humans. Our ﬁndings suggest
speciﬁc targets in humans that warrant further mechanis-
tic focus. For example, induction of speciﬁc SOCS pro-
teins and downregulation of IRS-1 are likely to play roles
in the inﬂammatory induction of adipose and systemic IR
in humans. This work also provides a human experimen-
tal model for studies of novel therapeutics targeting
systemic and adipose inﬂammation in IR and its meta-
bolic consequences.
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